Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders

Summary

Anxiety disorders are the most common mental disorders in community settings, and they are associated with significant psychological distress, functional and social impairment. Although pharmacological and psychological treatments for anxiety and depression have existed for several years now, only a minority of anxiety disorder sufferers are treated according to guidelines. Cognitive behavior therapy (CBT) is the most consistently efficacious psychological treatment for anxiety disorders, but implementation of CBT in primary care is challenging due to limited resources. Recent studies indicate that transdiagnostic group CBT for multiple anxiety disorders could be a promising alternative to individual CBT in primary care. The aim of the study is to examine the effectiveness of group CBT for anxiety disorders as a complement to usual care. The clinical trial will be conducted in three Health and Social Services Centers in the province of Québec (i.e. Sherbrooke, Laval and Québec). Patients will be French-speaking adults with anxiety disorders, and they will be randomly assigned to one of two treatment conditions: a) Transdiagnostic group CBT (12 weekly 2-hour sessions), b) usual care. The transdiagnostic group CBT will be offered as a differed intervention to participants in the usual care group after the 8-month follow up. Participants in both study arms will undergo a baseline clinical evaluation as well as outcome assessment interviews at post-treatment, 4, 8, and 12 month follow-up time-points. The primary study results will include improvement on a questionnaire on anxiety symptoms. Widespread implementation of group CBT could lead to better outcomes for a large number of patients living with anxiety.

Conditions

• Panic Disorder
• Agoraphobia
• Social Anxiety Disorder
• Generalized Anxiety Disorder

Interventions

BEHAVIORAL

Transdiagnostic Cognitive-Behavioral Therapy

Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.

Sponsors & Collaborators

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke

  collaborator OTHER

• CISSS de Laval

  collaborator UNKNOWN

• Integrated University Health and Social Services Center of the Capitale-Nationale

  collaborator OTHER

• Université de Sherbrooke

  lead OTHER

Principal Investigators

• Pasquale Roberge, Ph.D. · Université de Sherbrooke

• Martin D. Provencher, Ph.D. · Laval University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-09-12

Primary Completion

2018-06-15

Completion

2019-07-10

Countries

• Canada

Study Locations